This study applied a novel PPARγ agonist, ligustrazine piperazine derivative, to treat Alzheimer’s disease and found that PPARγ activation reduced Aβ40 and Aβ42 levels in vivo and in vitro and improved cognitive impairment in mice [37]. This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.